首页> 外文期刊>Cell cycle >A distinct 'side population' of cells in human tumor cells: implications for tumor biology and therapy.
【24h】

A distinct 'side population' of cells in human tumor cells: implications for tumor biology and therapy.

机译:人肿瘤细胞中细胞的独特“侧群”:对肿瘤生物学和治疗的意义。

获取原文
获取原文并翻译 | 示例
           

摘要

Stem cells have an extensive capacity to proliferate, differentiate and self-renew. In many mammals, including humans, an adult stem cell subpopulation termed the "side population" (SP) has been identified. SP cells can rapidly efflux lipophilic fluorescent dyes to produce a characteristic profile based on fluorescence-activated flow cytometric analysis. Previous studies have demonstrated SP cells in bone marrow obtained from patients with acute myeloid leukemia, suggesting that these cells might be candidate leukemic stem cells, and recent studies have found a SP of tumor progenitor cells in human solid tumors. These new data indicate that the ability of malignant SP cells to expel anticancer drugs may directly improve their survival and sustain their clonogenicity during exposure to cytostatic drugs, allowing disease recurrence when therapy is withdrawn. Identification of a tumor progenitor population with intrinsic mechanisms for cytostatic drug resistance might also provide clues for improved therapeutic intervention.
机译:干细胞具有广泛的增殖,分化和自我更新的能力。在包括人类在内的许多哺乳动物中,已经确定了成年干细胞亚群,称为“侧群”(SP)。 SP细胞可以基于荧光激活的流式细胞仪分析快速排出亲脂性荧光染料,以产生特征性特征。先前的研究已经证明了急性髓性白血病患者骨髓中的SP细胞,这暗示这些细胞可能是候选的白血病干细胞,并且最近的研究已经发现了人类实体瘤中肿瘤祖细胞的SP。这些新数据表明,恶性SP细胞排出抗癌药物的能力可能直接提高其存活率,并在暴露于细胞抑制剂的过程中维持其克隆性,从而在撤回治疗后使疾病复发。具有细胞抑制药物抗性的内在机制的肿瘤祖细胞群的鉴定也可能为改善治疗干预提供线索。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号